En randomiseret, international undersøgelse for at vurdere sikkerheden ved iTind sammenlignet med UroLift (MT-08)
En post-market, prospektiv, randomiseret, kontrolleret, multicenter international undersøgelse for at vurdere sikkerheden af den midlertidigt implanterede Nitinol-enhed (iTind) sammenlignet med UroLift®-systemet hos personer med symptomatisk benign prostatahyperplasi (BPH)
The study objective is to evaluate the efficacy and safety of the iTind device compared to UroLift.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Both iTind and UroLift are minimally invasive treatment options for relieving lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The iTind device is a temporary, self-expanding nitinol implant that remains in place for 5 to 7 days to reshape the prostatic urethra through localized ischemic pressure and tissue remodeling. In contrast, the UroLift system involves the permanent placement of transprostatic implants that retract the enlarged lateral lobes of the prostate to widen the urethral lumen.
This study is designed to directly compare the safety and effectiveness of the iTind device versus the UroLift system in treating LUTS due to BPH.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Melanie Bonds, MS
- Telefonnummer: +1-703-851-4615
- E-mail: Melanie.Bonds@olympus.com
Studiesteder
-
-
-
Dunfermline, Det Forenede Kongerige, KY12 0SU
- Rekruttering
- Queen Margaret Hospital
-
Ledende efterforsker:
- Feras Al Jaafari, MD
-
Kontakt:
- Keith Boath
- Telefonnummer: 20951 +44-1383-623623
- E-mail: Keith.boath@nhs.scot
-
London, Det Forenede Kongerige, GU16 7UJ
- Rekruttering
- Frimley Park Hospital
-
Ledende efterforsker:
- Neil Barber, MD
-
Kontakt:
- Reynette Baroman
- E-mail: r.baroman@nhs.net
-
Norwich, Det Forenede Kongerige, NR4 7UY
- Rekruttering
- Norfolk & Norwich University Hospital
-
Ledende efterforsker:
- Mark Rochester, MD
-
Kontakt:
- Catherine Rennie
- Telefonnummer: +44-1603 646105
- E-mail: catherine.rennie@nnuh.nhs.uk
-
-
Middlesex
-
Isleworth, Middlesex, Det Forenede Kongerige, TW7 6AF
- Rekruttering
- Chelsea and Westminster Hospital
-
Ledende efterforsker:
- Samuel Bishara, MD
-
Kontakt:
- Farrah Akkouch
- Telefonnummer: +44 (0)20 321 5181
- E-mail: chelwest.wmh.olympus@nhs.net
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85054
- Rekruttering
- Mayo Clinic Arizona
-
Ledende efterforsker:
- Mitchell Humphreys, MD
-
Kontakt:
- Rev Vilasan Shylaja
- Telefonnummer: 480-574-1466
- E-mail: VilasanShylaja.Revathy@mayo.edu
-
Tucson, Arizona, Forenede Stater, 85704
- Afsluttet
- Arizona Urology Specialists
-
-
California
-
Fresno, California, Forenede Stater, 93720
- Rekruttering
- Urology Associates of Central California
-
Ledende efterforsker:
- William Schiff, MD
-
Kontakt:
- Joe Vidal
- Telefonnummer: 559-321-2919 559-720-3646
- E-mail: jvidal@urologyassociates.net
-
Sacramento, California, Forenede Stater, 95823
- Rekruttering
- Golden State Urology
-
Ledende efterforsker:
- Prithipal Sethi, MD
-
Kontakt:
- Sehaj Sethi
- Telefonnummer: 308 916-245-8888
- E-mail: ssethi@goldenstateurology.com
-
-
Illinois
-
Evanston, Illinois, Forenede Stater, 60201
- Afsluttet
- NorthShore University Health System Research Institute
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70119
- Aktiv, ikke rekrutterende
- Southeast Louisiana Veterans Health Care System
-
-
Minnesota
-
Woodbury, Minnesota, Forenede Stater, 55125
- Trukket tilbage
- Minnesota Urology
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68124
- Rekruttering
- The Urology Center
-
Ledende efterforsker:
- Sida Niu, MD
-
Kontakt:
- Amy Nelson
- Telefonnummer: 402-397-7989
- E-mail: anelson@adultpediatricuro.com
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89121
- Rekruttering
- Pacific West Urology
-
Kontakt:
- John Dull
- Telefonnummer: 702-321-8045
- E-mail: john.dull@pacificwesturology.com
-
Ledende efterforsker:
- Joel Abbott, MD
-
-
New York
-
Syosset, New York, Forenede Stater, 11791
- Rekruttering
- Feinstein Institutes for Medical Research / Northwell Health
-
Ledende efterforsker:
- Bilal Chughtai, MD
-
Kontakt:
- Jennifer Polo
- Telefonnummer: 516-628-5926
- E-mail: jpolo1@northwell.edu
-
-
Tennessee
-
Germantown, Tennessee, Forenede Stater, 38138
- Rekruttering
- The Conrad Pearson Clinic
-
Ledende efterforsker:
- Adam Stewart, MD
-
Kontakt:
- Jessica Parks
- Telefonnummer: 901-464-2711
- E-mail: jessica.parks@conradpearson.com
-
-
Texas
-
Austin, Texas, Forenede Stater, 78705
- Rekruttering
- Midtown Urology Associates
-
Ledende efterforsker:
- Tyler McClintock, MD
-
Kontakt:
- Andrew Barger
- Telefonnummer: 512-451-7935
- E-mail: APBarger@cimplify.net
-
Houston, Texas, Forenede Stater, 77027
- Rekruttering
- Houston Metro Urology
-
Kontakt:
- Lena Ellis
- Telefonnummer: 713-634-4405
- E-mail: lena.ellis@hmutx.com
-
Ledende efterforsker:
- Mark Sutton, MD
-
San Antonio, Texas, Forenede Stater, 78240
- Rekruttering
- The Urology Place
-
Ledende efterforsker:
- Naveen Kella, MD
-
Kontakt:
- Raji Thiruppathiraj
- Telefonnummer: 210-617-3670
- E-mail: raji@theupi.com
-
-
Virginia
-
Alexandria, Virginia, Forenede Stater, 22311
- Rekruttering
- Potomac Urology Center
-
Ledende efterforsker:
- Nilay Gandhi, MD
-
Kontakt:
- Chamin Lim
- Telefonnummer: 423 703-680-2111
- E-mail: clim@potomacurology.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Diagnosis of lower urinary tract symptoms presumed to be secondary to benign prostatic enlargement causing bladder outlet obstruction for which treatment is recommended
- Willing and able to provide informed consent
- Males ≥ 50 years of age or older
- PSA < 4 ng/ml or if the PSA is 4 - 10 ng/ml, prostate cancer must be ruled out to the satisfaction of the Principal Investigator (PI) by local standard of care methods within prior 6 months
- Prostate volume up to 75 cc (inclusive) documented by cross-sectional imaging (TRUS, MRI, etc.). Results from standard of care imaging may be accepted up to 6 months prior to Screening
- International Prostate Symptom Score (IPSS) for urinary symptoms ≥ 13
- Maximum urinary flow rate (Qmax) of ≤ 15 mL/sec and ≥ 5 mL/sec (voided volume must be ≥ 125 mL)
- Willing and able to complete all study visits including questionnaires at baseline and at follow-up visits
Exclusion Criteria:
- History of prostate cancer or suspected, should be ruled out to the satisfaction of the PI by local standard of care methods within prior 6 months
- Confirmed bladder cancer within the last 2 years or currently suspected bladder cancer
- History of acute bacterial prostatitis within the last 2 years
- Median lobe obstruction of the prostate as confirmed by cross-sectional imaging
- PSA value > 10 ng/ml
- Contraindicated for iTind or UroLift as determined by the PI
- Neurogenic bladder and/or sphincter abnormalities due to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes or other neurological disorders that affect bladder function
- Clinically significant bladder diverticulum
- Diagnosed with urethral stricture, meatal stenosis, bladder neck contracture, rectal disease, artificial urinary sphincter, incompetent sphincter, urinary incontinence due to incompetent sphincter
- Prior rectal surgery (other than hemorrhoidectomy) or history of rectal disease treatment if the therapy may potentially cause injury to site (e.g., if a transrectal probe is used), pelvic radiotherapy or radical pelvic surgery, urinary diversion surgery, prostate surgery, balloon dilation, urethral stent implantation, laser prostatectomy, or any other invasive treatment to the prostate, or penile prosthesis if it may prevent insertion of the iTind or UroLift device
- An active urinary tract infection during randomization
- Clinically significant hematuria within the last 3 months or ongoing cystolithiasis
- Prostate volume > 75 cc
- Post-void residual volume (PVR) > 250 mL
- Actively using catheterization or unable to void naturally
- Unable to complete a 2-week washout period for alpha blockers prior to procedure or unable to discontinue 5ARIs or daily use of PDE5 inhibitors by the time of procedure
- Taking anti-platelet or anticoagulants (except low dose aspirin - 81 mg - 100 mg) within the last 7 days prior to procedure
- Known or suspected allergy to nickel, titanium or polyester/polypropylene
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: iTind arm
The iTind is a minimally invasive temporary implant |
The iTind is implemented for 5-7 days |
|
Aktiv komparator: UroLift
The UroLift is a minimally invasive permanent implant |
UroLift is a minimally invasive procedure where permanent implants are placed in the prostate. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 3 months
Tidsramme: 3 months
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 3 months |
3 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 12 months
Tidsramme: 12 month
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 12 months |
12 month
|
|
Incidence of all intraoperative and post-operative adverse events (AEs) (i.e., related to procedure and/or device) through 3 months post-procedure.
Tidsramme: 3 month
|
Incidence of all intraoperative and post-operative adverse events (AEs) (i.e., related to procedure and/or device) through 3 months post-procedure. |
3 month
|
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 1, 6, 24, and 36 months
Tidsramme: 1, 6, 24, and 36 months
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 1, 6, 24, and 36 months |
1, 6, 24, and 36 months
|
|
Difference in change of QoL scores (SHIM, MSHQ-EjD, SF-6D) from baseline between iTind and UroLift at 1, 3, 6, 12, 24, and 36 months
Tidsramme: 1, 3, 6, 12, 24, and 36 months
|
Difference in change of QoL scores (SHIM, MSHQ-EjD, SF-6D) from baseline between iTind and UroLift at 1, 3, 6, 12, 24, and 36 months |
1, 3, 6, 12, 24, and 36 months
|
|
Difference in rate of re-intervention between iTind and UroLift groups at 1, 3, 6, 12, 18, 24, and 36 months
Tidsramme: 1, 3, 6, 12, 18, 24, and 36 months
|
Difference in rate of re-intervention between iTind and UroLift groups at 1, 3, 6, 12, 18, 24, and 36 months |
1, 3, 6, 12, 18, 24, and 36 months
|
|
Difference in reporting between iTind and UroLift groups at 1, 6, 12, 18, 24, and 36, months •Overall incidence of procedure and/or device related adverse events
Tidsramme: 1, 6, 12, 18, 24, and 36, months
|
Difference in reporting between iTind and UroLift groups at 1, 6, 12, 18, 24, and 36, months •Overall incidence of procedure and/or device related adverse events |
1, 6, 12, 18, 24, and 36, months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Neil Barber, MD, Frimley Park Hospital
- Ledende efterforsker: Bilal Chughtai, MD, Northwell Health
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- MT-08
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .